论文部分内容阅读
目的研究并分析纳美芬对Ⅱ型呼吸衰竭新生儿的临床治疗效果。方法商丘市第四人民医院儿科门诊于2011年1月1日-2013年1月31日共收治Ⅱ型呼吸衰竭新生儿80例,将其随机分为两组,每组40例,对照组在常规治疗的基础上运用尼可刹米进行治疗,观察组在常规治疗的基础上运用纳美芬进行治疗,对比上述两组患者的临床治疗总有效率,并最终确定治疗Ⅱ型呼吸衰竭新生儿的最佳治疗方式。结果观察组患者的临床治疗效果与对照组患者相比具有明显优越性,观察组患者的临床治疗总有效率为97.5%,与对照组患者相比,差异具有统计学意义(P<0.05)。结论对于Ⅱ型呼吸衰竭新生儿而言,运用纳美芬进行治疗的疗效明显优于尼可刹米,其具有安全、有效等特点,值得推广。
Objective To study and analyze the effect of nalmefene on neonates with type Ⅱ respiratory failure. Methods Pediatric outpatient department of No.4 People’s Hospital of Shangqiu City was treated 80 newborns with type Ⅱ respiratory failure from Jan. 1, 2011 to Jan. 31, 2013, which were randomly divided into two groups, 40 cases in each group. The control group The conventional treatment based on the use of nikethamide for treatment, the observation group on the basis of conventional treatment with nalmefene for treatment, compared with the total effective rate of clinical treatment of the two groups of patients, and ultimately determine the treatment of neonatal respiratory failure Ⅱ The best treatment. Results The clinical efficacy of the observation group was significantly superior to that of the control group. The total effective rate of clinical observation in the observation group was 97.5%, which was significantly different from that in the control group (P <0.05). Conclusion For the newborn infants with type Ⅱ respiratory failure, the effect of nalmefene treatment is obviously better than that of nikethamide, which is safe, effective and worthy of promotion.